RHHBY vs. NOV.DE
RHHBY (Roche Holding AG) and NOV.DE (Novo Nordisk A/S) are both stocks. Both are in the Healthcare sector — RHHBY in Drug Manufacturers - General, NOV.DE in Biotechnology. Over the past 10 years, RHHBY returned 7.66%/yr vs 9.87%/yr for NOV.DE. At a 0.30 correlation, their price movements are largely independent.
Performance
RHHBY vs. NOV.DE - Performance Comparison
Loading charts...
Different Trading Currencies
RHHBY is traded in USD, while NOV.DE is traded in EUR. To make them comparable, the NOV.DE values have been converted to USD using the latest available exchange rates.
Returns By Period
In the year-to-date period, RHHBY achieves a 1.04% return, which is significantly higher than NOV.DE's -11.61% return. Over the past 10 years, RHHBY has underperformed NOV.DE with an annualized return of 7.66%, while NOV.DE has yielded a comparatively higher 9.87% annualized return.
RHHBY
- 1D
- -1.81%
- 1M
- -1.06%
- YTD
- 1.04%
- 6M
- 6.55%
- 1Y
- 27.52%
- 3Y*
- 12.73%
- 5Y*
- 4.71%
- 10Y*
- 7.66%
NOV.DE
- 1D
- 4.37%
- 1M
- -3.02%
- YTD
- -11.61%
- 6M
- -5.22%
- 1Y
- -38.05%
- 3Y*
- -15.34%
- 5Y*
- 4.12%
- 10Y*
- 9.87%
RHHBY vs. NOV.DE - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
RHHBY Roche Holding AG | 1.04% | 52.86% | 0.23% | -4.02% | -22.21% | 20.20% | 9.94% | 33.47% | 2.16% | 14.32% |
NOV.DE Novo Nordisk A/S | -11.61% | -38.94% | -14.91% | 54.32% | 23.37% | 59.95% | 24.41% | 32.53% | 13.85% | 53.99% |
Correlation
The correlation between RHHBY and NOV.DE is 0.24, which is low. Their price movements are largely independent, making them effective diversification partners.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | 0.24 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.20 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.26 |
Correlation (10Y) Calculated over the trailing 10-year period | 0.32 |
Correlation (All Time) Calculated using the full available price history since May 30, 2007 | 0.30 |
The correlation between RHHBY and NOV.DE shifts across timeframes, from 0.20 (3 years) to 0.32 (10 years), reflecting how their relationship changes across market environments.
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
RHHBY vs. NOV.DE — Risk / Return Rank
RHHBY
NOV.DE
RHHBY vs. NOV.DE - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Roche Holding AG (RHHBY) and Novo Nordisk A/S (NOV.DE). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| RHHBY | NOV.DE | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | +1.68 | ||
| Sortino ratioReturn per unit of downside risk | +2.34 | ||
| Omega ratioGain probability vs. loss probability | 1.20 | 0.90 | +0.30 |
| Calmar ratioReturn relative to maximum drawdown | 1.43 | -0.67 | +2.10 |
| Martin ratioReturn relative to average drawdown | 3.49 | -1.00 | +4.49 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| RHHBY | NOV.DE | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 1.01 | -0.67 | +1.68 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.20 | 0.11 | +0.10 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | 0.34 | 0.29 | +0.05 |
Sharpe Ratio (All Time)Calculated using the full available price history | 0.35 | 0.47 | -0.12 |
Drawdowns
RHHBY vs. NOV.DE - Drawdown Comparison
The maximum RHHBY drawdown since its inception was -45.73%, smaller than the maximum NOV.DE drawdown of -74.69%. Use the drawdown chart below to compare losses from any high point for RHHBY and NOV.DE.
Loading charts...
Drawdown Indicators
| RHHBY | NOV.DE | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -45.73% | -74.69% | +28.96% |
Max Drawdown (1Y)Largest decline over 1 year | -19.38% | -54.35% | +34.97% |
Max Drawdown (3Y)Largest decline over 3 years | -23.46% | -74.69% | +51.23% |
Max Drawdown (5Y)Largest decline over 5 years | -40.88% | -74.69% | +33.81% |
Max Drawdown (10Y)Largest decline over 10 years | -40.88% | -74.69% | +33.81% |
Current DrawdownCurrent decline from peak | -13.99% | -68.09% | +54.10% |
Average DrawdownAverage peak-to-trough decline | -12.84% | -12.88% | +0.04% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.91% | 36.39% | -28.48% |
Volatility
RHHBY vs. NOV.DE - Volatility Comparison
The current volatility for Roche Holding AG (RHHBY) is 8.10%, while Novo Nordisk A/S (NOV.DE) has a volatility of 8.81%. This indicates that RHHBY experiences smaller price fluctuations and is considered to be less risky than NOV.DE based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| RHHBY | NOV.DE | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 8.10% | 8.81% | -0.71% |
Volatility (6M)Calculated over the trailing 6-month period | 18.55% | 40.53% | -21.98% |
Volatility (1Y)Calculated over the trailing 1-year period | 27.48% | 54.66% | -27.18% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 23.39% | 38.50% | -15.11% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 22.58% | 33.85% | -11.27% |
Dividends
RHHBY vs. NOV.DE - Dividend Comparison
RHHBY's dividend yield for the trailing twelve months is around 3.07%, less than NOV.DE's 4.11% yield.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
NOV.DE Novo Nordisk A/S | 4.11% | 3.54% | 1.58% | 1.01% | 1.17% | 1.27% | 1.98% | 2.08% | 27.19% | 2.27% | 3.67% | 1.25% |
RHHBY Roche Holding AG | 3.07% | 2.69% | 3.87% | 3.55% | 3.23% | 1.57% | 1.66% | 1.70% | 3.58% | 3.25% | 3.57% | 2.91% |
Financials
RHHBY vs. NOV.DE - Financials Comparison
This section allows you to compare key financial metrics between Roche Holding AG and Novo Nordisk A/S. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
RHHBY and NOV.DE have a correlation of 0.24, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
Find the right allocation for RHHBY and NOV.DE
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer